KIDS

MKT CAP:$411M

OrthoPediatrics Corp.

Market Cap

$411M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$16.65-$0.91 (-5.18%)

Apr 20, 2026

Company Details

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company off...

CEO

David R. Bailey

IPO Date

Oct 13, 2017

Website

www.orthopediatrics.com

Key Metrics TTM

Revenue

$236M

+15.4% YoY

Net Income

-$40M

EPS (Diluted)

-$1.69

Free Cash Flow

-$16M

Revenue / Share

$10.02

Gross Margin

73.1%

Operating Margin

-12.3%

Net Margin

-16.8%

FCF Margin

-6.8%

P/S

1.7x

P/E

—

Earnings Reports

Q1 2026

May 6, 2026

PENDING

FY 2025

Mar 4, 2026

$236M+15.4%EPS -$1.69

Q4 2025

Mar 4, 2026

$62M+17.0%EPS -$0.43

Q3 2025

Oct 29, 2025

$61M+12.2%EPS -$0.50

Q2 2025

Aug 6, 2025

$61M+15.7%EPS -$0.30

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$25M	$18M	-$6M
Q1 22	$23M	$19M	-$6M
Q2 22	$33M	$25M	-$4M
Q4 22	$31M	$21M	-$8M
Q1 23	$32M	$24M	-$9M
Q2 23	$40M	$30M	-$6M
Q3 23	$40M	$31M	-$5M
Q4 23	$38M	$27M	-$8M
Q1 24	$45M	$32M	-$10M
Q2 24	$53M	$41M	-$6M
Q3 24	$55M	$40M	-$6M
Q4 24	$53M	$36M	-$14M
Q1 25	$52M	$38M	-$11M
Q2 25	$61M	$44M	-$11M
Q3 25	$61M	$45M	-$5M
Q4 25	$62M	$45M	-$2M

Valuation

Quarter	P/S	P/E
Q4 21	4.2x	—
Q1 22	4.1x	—
Q2 22	3.9x	—
Q4 22	3.7x	—
Q1 23	3.5x	—
Q2 23	3.0x	—
Q3 23	2.9x	—
Q4 23	2.8x	—
Q1 24	2.5x	—
Q2 24	2.3x	—
Q3 24	2.2x	—
Q4 24	2.0x	—
Q1 25	1.9x	—
Q2 25	1.9x	—
Q3 25	1.8x	—
Q4 25	1.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$1M	-$3M
Q1 22	-$4M	-$8M
Q2 22	-$8M	-$13M
Q4 22	-$3M	-$3M
Q1 23	-$6M	-$11M
Q2 23	-$4M	-$10M
Q3 23	-$9M	-$11M
Q4 23	-$8M	-$13M
Q1 24	-$7M	-$13M
Q2 24	-$6M	-$13M
Q3 24	-$10M	-$12M
Q4 24	-$4M	-$4M
Q1 25	-$4M	-$8M
Q2 25	-$10M	-$14M
Q3 25	-$581.0K	-$3M
Q4 25	$10M	$10M

Capital Expenditures

Quarter	CapEx
Q4 21	$2M
Q1 22	$4M
Q2 22	$5M
Q4 22	$523.0K
Q1 23	$5M
Q2 23	$6M
Q3 23	$2M
Q4 23	$6M
Q1 24	$6M
Q2 24	$7M
Q3 24	$1M
Q4 24	$262.0K
Q1 25	$4M
Q2 25	$3M
Q3 25	$3M
Q4 25	$599.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	+31.1%	-4.1%
Q1 22	+9.1%	+8.6%
Q2 22	+23.3%	+24.1%
Q4 22	+23.6%	+36.8%
Q1 23	+27.3%	+32.3%
Q2 23	+68.9%	+51.5%
Q3 23	+21.4%	+21.3%
Q4 23	+21.4%	+16.2%
Q1 24	+41.5%	+35.4%
Q2 24	+33.5%	+29.5%
Q3 24	+36.5%	+35.2%
Q4 24	+40.0%	+46.1%
Q1 25	+17.3%	+16.5%
Q2 25	+15.7%	+22.7%
Q3 25	+12.2%	+9.9%
Q4 25	+17.0%	-3.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$2M	6.7%
Q1 22	$2M	6.5%
Q2 22	$2M	5.4%
Q4 22	$2M	5.5%
Q1 23	$2M	6.7%
Q2 23	$3M	8.3%
Q3 23	$2M	5.9%
Q4 23	$3M	7.3%
Q1 24	$3M	6.3%
Q2 24	$3M	5.6%
Q3 24	$4M	7.2%
Q4 24	$4M	7.4%
Q1 25	$4M	7.4%
Q2 25	$5M	8.6%
Q3 25	$4M	6.9%
Q4 25	$4M	7.2%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 21	$2M	$12M	$10M
Q1 22	$2M	$13M	$10M
Q2 22	$2M	$15M	$12M
Q4 22	$2M	$17M	$11M
Q1 23	$2M	$18M	$12M
Q2 23	$3M	$19M	$14M
Q3 23	$3M	$18M	$14M
Q4 23	$3M	$20M	$12M
Q1 24	$3M	$25M	$14M
Q2 24	$3M	$27M	$17M
Q3 24	$3M	$26M	$17M
Q4 24	$3M	$24M	$17M
Q1 25	$2M	$30M	$17M
Q2 25	$2M	$30M	$19M
Q3 25	$2M	$29M	$19M
Q4 25	$2M	$30M	$18M

Revenue Segments

Quarter	Spine	Sports Medicine And Other	Trauma and Deformity	Trauma And Deformity
Q1 22	$6M	$918.0K	$17M	—
Q2 22	$9M	$939.0K	$23M	—
Q1 23	$7M	$1M	—	$23M
Q2 23	$11M	$1M	—	$28M
Q3 23	$10M	$862.0K	—	$29M
Q1 24	$10M	$1M	—	$33M
Q2 24	$14M	$1M	—	$38M
Q3 24	$16M	$1M	—	$38M
Q1 25	$14M	$880.0K	—	$38M
Q2 25	$19M	$905.0K	—	$42M
Q3 25	$16M	$846.0K	—	$44M

Revenue by Geography

Quarter	Non-US	United States
Q1 22	$5M	$18M
Q2 22	$8M	$25M
Q4 22	$8M	$23M
Q1 23	$8M	$24M
Q2 23	$10M	$30M
Q3 23	$11M	$29M
Q4 23	$9M	$28M
Q1 24	$10M	$34M
Q2 24	$12M	$41M
Q3 24	$12M	$43M
Q1 25	$12M	$41M
Q2 25	$13M	$48M
Q3 25	$13M	$49M
Q4 25	$13M	$49M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$18M	$27M	$45M
Q2 22	$37M	$14M	$51M
Q3 22	$35M	$85M	$120M
Q4 22	$9M	$109M	$118M
Q1 23	$35M	$73M	$108M
Q2 23	$10M	$83M	$93M
Q3 23	$11M	$72M	$82M
Q4 23	$31M	$49M	$80M
Q1 24	$22M	$26M	$48M
Q2 24	$29M	$0	$29M
Q3 24	$51M	$25M	$76M
Q4 24	$44M	$25M	$69M
Q1 25	$33M	$25M	$59M
Q2 25	$45M	$26M	$70M
Q3 25	$17M	$41M	$58M
Q4 25	$20M	$41M	$61M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	19M	+0.1%	+1.0%
Q1 22	19M	+0.3%	+0.9%
Q2 22	20M	+2.2%	+2.7%
Q4 22	22M	+13.5%	+16.5%
Q1 23	23M	+0.1%	+16.6%
Q2 23	23M	+0.9%	+17.2%
Q3 23	23M	+0.3%	+15.0%
Q4 23	23M	-0.0%	+1.3%
Q1 24	23M	+0.3%	+1.4%
Q2 24	23M	+1.4%	+1.9%
Q3 24	23M	+0.1%	+1.8%
Q4 24	23M	+0.0%	+1.8%
Q1 25	23M	+0.3%	+1.8%
Q2 25	23M	+0.5%	+0.9%
Q3 25	23M	+0.3%	+1.1%
Q4 25	24M	+0.7%	+1.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$186.6K	133
Q1 22	$176.1K	133
Q2 22	$247.6K	133
Q4 22	$152.7K	203
Q1 23	$155.6K	203
Q2 23	$194.9K	203
Q3 23	$196.9K	203
Q4 23	$152.3K	247
Q1 24	$180.9K	247
Q2 24	$213.8K	247
Q3 24	$220.9K	247
Q4 24	$93.7K	562
Q1 25	$93.3K	562
Q2 25	$108.7K	562
Q3 25	$109.0K	562
Q4 25	$7.7K	8K

Revenue / Employee